Evidence map›Paper›PMID 34341617›Full record

ReviewMonatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde2021

[Molecular medicine: pathobiochemistry as the key to personalized treatment of inherited diseases].

J A Mayr, R G Feichtinger, M T Achleitner, K Brugger, K Kutsam, J Spenger, J Koch, P Hofbauer, F B Lagler, W Sperl and 2 more

Abstract readEnglish AbstractReview
In one paragraph

Review in Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J A MayrUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
R G FeichtingerUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
M T AchleitnerUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
K BruggerUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
K KutsamUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
J SpengerUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
J KochUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
P HofbauerArzneimittelproduktion, Landesapotheke Salzburg, Betrieb des Landes Salzburg, Müllner Hauptstr. 50, 5020 Salzburg, Österreich.
F B LaglerUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
W SperlUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
D WeghuberUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.
S B WortmannUniversitätsklinik für Kinder- und Jugendheilkunde, Paracelsus Medizinische Privatuniversität, Müllner Hauptstr. 48, 5020 Salzburg, Österreich.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic defects are often still regarded as a life-long fate, which one has to cope with. It is true that in many cases an inherited disposition may lead to a severe disease; however, it is also true that the number of genetic defects with a treatment option is continuously increasing and in some of them the onset of disease symptoms can even be totally prevented. Knowledge of the precise molecular pathomechanism is often the basis for a treatment concept. Genome-wide sequencing has tremendously increased the possibility to identify a genetic defect and its broad application has meanwhile made a decisive contribution in routine diagnostics. After identifying a genetic alteration, it is still necessary to investigate the pathobiochemical consequences on the cellular and systemic level. This can be a time-consuming process since not all functional consequences can be immediately recognized. In the case of metabolic defects the treatment strategy can either be a supplementation of missing products or a removal of toxic substrates. The residual function of affected pathways can also often be improved. Recently, the direct correction of the affected genetic defects has become a treatment option for a selected number of diseases. As the first symptoms of disease usually occur early in life, pediatrics has a pioneering role in developing treatment strategies.

Indexed as

DetoxificationGene therapyMetabolic diseasesTherapeutic substitutionWhole genome sequencing

Identifiers

PMID34341617
PMCPMC8320310

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.